News | December 13, 2022
Evonik invests in US based biopharma company ‘Allay Therapeutics’
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.
Study achieves primary endpoint of radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
